2-2-3-3-tetramethylcyclopropanecarbonylurea and Seizures

2-2-3-3-tetramethylcyclopropanecarbonylurea has been researched along with Seizures* in 3 studies

Other Studies

3 other study(ies) available for 2-2-3-3-tetramethylcyclopropanecarbonylurea and Seizures

ArticleYear
Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    As part of our ongoing research on potential new antiepileptic drugs (AEDs), a series of tetramethylcyclopropanecarboxamide derivatives containing benzene ring were designed, synthesized, and evaluated for anticonvulsant activities in the murine maximal electroshock (MES) and subcutaneous pentylenetetrazole (scMet) seizure tests. The most potent compound emerging from this study was N-(2,2,3,3-tetramethylcyclopropanecarboxamide)-p-phenyl-sulfonamide (21), possessing an ED(50) value of 26mg/kg in the rat-MES test and a remarkable PI (PI=TD(50)/ED(50)) value above 19. The better anticonvulsant potency of compound 21 and its wider safety margin compared to valproic acid (VPA) and zonisamide make it a potential candidate to become a new AED second-generation to VPA.

    Topics: Administration, Oral; Amides; Animals; Anticonvulsants; Cyclopropanes; Electroshock; Isoxazoles; Mice; Motor Activity; Rats; Seizures; Sulfonamides; Urea; Valproic Acid; Zonisamide

2008
Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug.
    Neuropharmacology, 2006, Volume: 51, Issue:4

    2,2,3,3-Tetramethylcyclopropanecarbonylurea (TMCU) is an amide derivative of a tetramethylcyclopropyl analogue of valproic acid (VPA), one of the leading antiepileptic drugs. Structural considerations used in the design of TMCU aimed to enhance the anticonvulsant potency of VPA and to prevent its two life-threatening side effects; i.e., teratogenicity and hepatotoxicity. The anticonvulsant activity of TMCU was evaluated in the MES, scMet, 6-Hz, scBic and scPic tests, and also in the hippocampal kindling model of partial seizures and lamotrigine-resistant amygdala kindling model of therapy-resistant seizures. Minimal motor impairment was determined using the rotorod test in mice and the positional sense test, muscle tone test, and gait and stance test in rats. The antinociceptive effect of TMCU was evaluated in the mouse formalin model of acute-tonic pain. The molecular mechanisms of action of TMCU were investigated in electrophysiological studies using the whole-cell patch-clamp technique. Teratogenicity studies were performed in a SWV/Fnn-mouse model of VPA-induced teratogenicity. TMCU hepatotoxicity was evaluated following 1-week intraperitoneal and oral administration of 50, 250 and 500 mg/kg doses to rats. In the hepatotoxicity study the blood levels of TMCU were evaluated at day 1 and day 7 of the treatment. TMCU mutagenicity was evaluated in the Ames test.

    Topics: Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Body Weight; Cells, Cultured; Cerebral Cortex; Cyclopropanes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Humans; Kindling, Neurologic; Male; Membrane Potentials; Mice; Models, Animal; Motor Activity; Neurons; Organ Size; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Seizures; Urea; Valproic Acid

2006
Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives.
    Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17

    Although valproic acid (VPA) is an extensively used antiepileptic drug for treatment of various kinds of epilepsies, it has been proven to possess two life-threatening side effects: hepatotoxicity and teratogenicity. Amide and urea derivatives of 2,2,3,3-tetramethylcyclopropanecarboxylic acid (TMCA) were prepared to discover lead compounds with clinical potential. In the amide and alkylamide series of TMCA derivatives, N-methoxy-2,2,3,3-tetramethylcyclopropanecarboxamide (21) was one of the most active compounds, having the subcutaneous metrazol test (scMet) ED50 values of 35 mg/kg in rats and 74 mg/kg in mice. In the maximal electroshock-induced seizure test (MES), this compound had ED50 values of 108 mg/kg in rats and 115 mg/kg in mice. Compound 21 was 18.5 and 4.5 times more potent than VPA in the corresponding rat tests. The most active compound in the series of urea derivatives was 2,2,3,3-tetramethylcyclopropanecarbonylurea (25), possessing MES ED50 values of 29 mg/kg in rats and 90 mg/kg in mice. In the scMet test this compound had ED50 values of 92 mg/kg in rats and 125 mg/kg in mice. The median toxic dose (TD50) in rats was 538 mg/kg, providing compound 25 with a wide safety margin and a protective index (TD50/ED50) of 18.5 in the MES test, which is about 12 times greater than that of VPA. Compounds 21 and 25 have the potential for development as novel potent and safe central nervous system active drugs with a broad spectrum of antiepileptic activity.

    Topics: Animals; Anticonvulsants; Convulsants; Cyclopropanes; Electroshock; Mice; Pentylenetetrazole; Polyunsaturated Alkamides; Rats; Seizures; Species Specificity; Structure-Activity Relationship; Urea; Valproic Acid

2004